An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...
Gastrointestinal involvement is common among patients with EGPA, with eosinophilic tissue infiltration, weight loss, and myalgia identified as significant predictors.
4mon
GlobalData on MSNEMA CHMP recommends AstraZeneca’s Fasenra to treat EGPAThe product is already approved in the US for EGPA treatment and as an add-on maintenance treatment for severe eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results